Latest Ratios: P/E Ratio 31.3x · EV/EBITDA 7.8x · ROE 11.5%. (2005–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $196M | $189M | $183M | $228M | $187M | $376M | $408M | $178M | $74M | $52M | $58M |
| Enterprise Value | $196M | $189M | $211M | $263M | $224M | $412M | $441M | $218M | $103M | $78M | $92M |
| P/E Ratio → | 31.26 | 28.94 | 76.82 | 263.50 | 10850.00 | 283.83 | 23.48 | 130.63 | — | — | — |
| P/S Ratio | 1.36 | 1.32 | 1.36 | 1.81 | 1.70 | 3.67 | 4.19 | 2.19 | 1.10 | 0.74 | 0.82 |
| P/B Ratio | 3.57 | 3.30 | 3.19 | 4.36 | 3.90 | 7.78 | 10.01 | 7.96 | 3.60 | 1.69 | 1.14 |
| P/FCF | 8.20 | 7.94 | 69.85 | 2152.36 | 76.62 | 226.21 | 121.17 | — | 23.86 | 13.11 | — |
| P/OCF | 8.01 | 7.75 | 8.97 | 20.33 | 10.68 | 20.50 | 20.11 | 12.81 | 6.47 | 6.90 | 7.29 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.32 | 1.57 | 2.09 | 2.04 | 4.02 | 4.53 | 2.69 | 1.54 | 1.10 | 1.30 |
| EV / EBITDA | 7.77 | 7.52 | 10.90 | 15.84 | 14.90 | 23.62 | 19.29 | 13.75 | 8.80 | 8.98 | 7.82 |
| EV / EBIT | 16.43 | 15.89 | 28.06 | 65.36 | 146.07 | 156.45 | 50.11 | 63.63 | 272.85 | — | 93.55 |
| EV / FCF | — | 7.95 | 80.47 | 2479.42 | 91.68 | 248.24 | 130.98 | — | 33.40 | 19.63 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.0% | 56.0% | 52.2% | 50.2% | 55.1% | 57.2% | 60.3% | 57.8% | 58.1% | 61.0% | 63.5% |
| Operating Margin | 8.3% | 8.3% | 5.1% | 3.3% | 1.5% | 2.8% | 9.1% | 4.3% | 0.6% | -5.4% | 1.4% |
| Net Profit Margin | 4.6% | 4.6% | 1.7% | 0.7% | 0.0% | 1.4% | 17.8% | 1.7% | -1.6% | -29.1% | -0.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.5% | 11.5% | 4.3% | 1.7% | 0.0% | 3.2% | 54.9% | 6.4% | -4.3% | -50.7% | -0.4% |
| ROA | 6.5% | 6.5% | 2.3% | 0.9% | 0.0% | 1.5% | 19.7% | 1.9% | -1.6% | -25.1% | -0.2% |
| ROIC | 12.5% | 12.5% | 6.0% | 3.6% | 1.5% | 2.7% | 9.7% | 4.7% | 0.6% | -4.0% | 0.9% |
| ROCE | 14.3% | 14.3% | 8.0% | 4.8% | 2.0% | 3.6% | 13.4% | 6.6% | 0.8% | -5.6% | 1.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.49 | 0.67 | 0.77 | 0.76 | 1.05 | 1.93 | 1.65 | 0.95 | 0.74 |
| Debt / EBITDA | 0.14 | 0.14 | 1.47 | 2.10 | 2.46 | 2.11 | 1.87 | 2.71 | 2.88 | 3.38 | 3.19 |
| Net Debt / Equity | — | 0.00 | 0.48 | 0.66 | 0.77 | 0.76 | 0.81 | 1.81 | 1.44 | 0.84 | 0.67 |
| Net Debt / EBITDA | 0.01 | 0.01 | 1.44 | 2.09 | 2.45 | 2.10 | 1.44 | 2.54 | 2.51 | 2.98 | 2.90 |
| Debt / FCF | — | 0.01 | 10.62 | 327.07 | 15.06 | 22.04 | 9.81 | — | 9.54 | 6.51 | — |
| Interest Coverage | 9.18 | 9.18 | 4.24 | 1.85 | 1.09 | 1.91 | 7.01 | 1.80 | 0.27 | -2.95 | 0.73 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.80 | 1.80 | 1.82 | 1.95 | 1.71 | 1.71 | 1.29 | 0.88 | 1.19 | 1.42 | 1.26 |
| Quick Ratio | 1.53 | 1.53 | 1.45 | 1.54 | 1.38 | 1.41 | 1.16 | 0.75 | 1.03 | 1.27 | 1.13 |
| Cash Ratio | 0.16 | 0.16 | 0.03 | 0.01 | 0.01 | 0.01 | 0.42 | 0.12 | 0.29 | 0.28 | 0.21 |
| Asset Turnover | — | 1.43 | 1.30 | 1.22 | 1.11 | 1.05 | 1.00 | 1.02 | 1.05 | 1.03 | 0.73 |
| Inventory Turnover | 11.71 | 11.71 | 9.87 | 9.79 | 10.24 | 11.13 | 12.87 | 11.81 | 12.48 | 15.71 | 11.89 |
| Days Sales Outstanding | — | 58.28 | 57.26 | 57.54 | 56.02 | 54.92 | 55.17 | 54.43 | 52.15 | 57.95 | 59.96 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.2% | 3.5% | 1.3% | 0.4% | 0.0% | 0.4% | 4.3% | 0.8% | — | — | — |
| FCF Yield | 12.2% | 12.6% | 1.4% | 0.0% | 1.3% | 0.4% | 0.8% | — | 4.2% | 7.6% | — |
| Buyback Yield | 5.6% | 5.8% | 1.1% | 0.6% | 3.6% | 0.5% | 0.4% | 0.4% | 14.2% | 0.1% | 0.1% |
| Total Shareholder Yield | 5.6% | 5.8% | 1.1% | 0.6% | 3.6% | 0.5% | 0.4% | 0.4% | 14.2% | 0.1% | 0.1% |
| Shares Outstanding | — | $21M | $22M | $22M | $22M | $22M | $22M | $21M | $21M | $23M | $23M |
CMS reimbursement rate volatility
Based on current market data, InfuSystem trades at a trailing P/E of 32.42, which appears elevated relative to its inconsistent earnings history and suggests that investors are pricing in significant future growth that has yet to materialize in the company's reported bottom-line results.
The forward P/E of 23.65 indicates that the market expects a meaningful recovery in profitability, yet the lack of a clear PEG ratio highlights the difficulty in justifying this premium given the recent deceleration in revenue. Investors should monitor whether the current valuation reflects a genuine growth trajectory or merely a speculative premium on the company's niche position in the home-based oncology market.
As reported in financial statements, InfuSystem's ROIC has struggled to gain traction, hovering at a modest 1.7% in 2026Q1, which indicates that the company is currently failing to generate returns that meaningfully exceed the typical cost of capital for medical equipment service providers.
The persistent gap between ROIC and ROE suggests that the company's capital allocation strategy has not yet successfully compounded value for shareholders. This trend warrants further investigation into whether the recent shift toward new therapy lines like NPWT will eventually drive the necessary operating leverage to improve these returns or if the asset-heavy nature of the business will continue to weigh on performance.
According to recent quarterly filings, the company's cash conversion cycle has fluctuated between 31 and 48 days over the last ten quarters, reflecting the inherent challenges of managing a complex billing environment where DSO remains elevated at 63 days as of 2026Q1.
The reliance on third-party payers creates a structural drag on cash flow, as evidenced by the persistent DPO levels that suggest the company is utilizing supplier credit to manage its own liquidity needs. This inefficiency in the cash conversion cycle implies that the company's operational health is highly sensitive to the speed of insurance reimbursements, which may limit its ability to scale rapidly without additional working capital support.
The most commonly misapplied metric for InfuSystem is the EV/EBITDA multiple, which obscures the company's true nature as a specialized healthcare service provider by treating its infusion pump fleet as a commoditized asset rather than a tool for generating recurring, high-margin service revenue.
By focusing on traditional equipment rental multiples, analysts may overlook the value of the company's proprietary billing infrastructure and payer network, which are the actual drivers of its competitive moat. A more appropriate approach would involve evaluating the company based on its recurring service revenue growth and the stability of its payer mix, rather than the capital intensity of its hardware fleet.
Includes 30+ ratios · 21 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying INFU stock.
InfuSystem Holdings, Inc.'s current P/E ratio is 31.3x. The historical average is 42.9x. This places it at the 67th percentile of its historical range.
InfuSystem Holdings, Inc.'s current EV/EBITDA is 7.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 10.3x.
InfuSystem Holdings, Inc.'s return on equity (ROE) is 11.5%. The historical average is -2.3%.
Based on historical data, InfuSystem Holdings, Inc. is trading at a P/E of 31.3x. This is at the 67th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
InfuSystem Holdings, Inc. has 56.0% gross margin and 8.3% operating margin.
InfuSystem Holdings, Inc.'s Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.